Difference between revisions of "Maprotiline-citalopram"

From Psychiatrienet
Jump to: navigation, search
Line 10: Line 10:
 
* '''Day 7:''' simultaneously start administration of citalopram in a normal dosage of 20 mg/day.
 
* '''Day 7:''' simultaneously start administration of citalopram in a normal dosage of 20 mg/day.
 
| info =  
 
| info =  
* Citalopram/escitalopram are a weak inhibitor of CYP2D6, which metabolizes maprotiline.   
+
* Citalopram is a weak inhibitor of CYP2D6, which metabolizes maprotiline.   
 
}}
 
}}

Revision as of 16:32, 9 March 2010

Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline
Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram

Switch medication from maprotiline to citalopram.

Nietinrijdenbord.png Stop maprotiline
  • Before day 1: gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
  • Day 1: reduce dosage of maprotiline to 50 mg/day.
  • Day 7: reduce dosage of maprotiline to 25 mg/day.
  • Day 14: stop administration of maprotiline.
Eenrichtingbord.png Start citalopram
  • Day 7: simultaneously start administration of citalopram in a normal dosage of 20 mg/day.
Infobord.png More information
  • Citalopram is a weak inhibitor of CYP2D6, which metabolizes maprotiline.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.